The RAPID Pathway Is the Other Side of the CMS Reset — and It Changes Who Wins
Dr. David Armstrong has spent thirty years watching clinically validated tools fail to reach patients at scale. In BTK's Signal Interview Series, he described a 33–41 day predictive window before foot ulceration — documented by his group more than two decades ago — sitting largely unmonetized and unutilized. The technology to close the loop now exists, he said. What's been missing is the willingness of payors and systems to be first.
Last week, CMS and FDA announced a structural attempt to remove one of the other barriers standing between that kind of innovation and the patients who need it.
The RAPID coverage pathway — Regulatory Alignment for Predictable and Immediate Device — is not a minor administrative update. It is a fundamental rewrite of how Breakthrough Devices move from FDA clearance to Medicare reimbursement. And for this market, the timing is not incidental.
What RAPID Actually Does
Under the current system, a company that earns FDA market authorization for a Class II or Class III Breakthrough Device then enters a separate, disconnected Medicare coverage determination process. That process takes approximately a year — often longer. FDA says the device works. CMS spends another year deciding whether Medicare will pay for it. During that gap, patients with Medicare as their primary payer cannot access the technology, and companies cannot build commercial momentum in their largest addressable market.
RAPID collapses that gap by design. CMS now participates in early and frequent engagement between FDA and device innovators during development — not after clearance. Evidence generated for FDA review is structured to simultaneously support Medicare coverage decisions. The clinical outcomes that matter for FDA premarket review are aligned, in advance, with the outcomes that matter for Medicare coverage.
The operational result: CMS will issue a proposed National Coverage Determination the same day an eligible device receives FDA market authorization. The statutory 30-day public comment period runs immediately. Medicare national coverage and payment could be in place as soon as two months after FDA clearance — compared to 12 months or more under the prior pathway.
Why This Is Directly Relevant to This Market
Dr. Armstrong's predictive thermometry work is one example. His Question 5 prediction from the BTK Signal Interview: within 24 months, a major U.S. payor will cover an at-home wearable for diabetic foot remission monitoring under a value-based contract tied to amputation reduction rather than RVU billing. His read: the actuarial case is already there. What has been missing is willingness to be first.
RAPID does not solve the payor willingness problem directly - it is a Medicare pathway, not a commercial insurance mechanism. But it changes the economics of the proof-of-concept problem. If a company developing a wearable for diabetic foot remission monitoring can move from FDA clearance to Medicare coverage in two months instead of fourteen, the capital required to bridge that gap shrinks dramatically. The commercial case to investors gets structurably easier to make. The pathway to first-mover scale — the thing that makes commercial payors follow — becomes shorter.
The same logic applies across multiple BTK-relevant innovation categories. Efemoral Medical's Efemoral Vascular Scaffold System holds FDA Breakthrough Device designation for infrapopliteal artery lesions in CLTI patients. Under the prior pathway, FDA clearance triggers a year-plus wait for Medicare coverage while the company attempts to build commercial traction in a BTK vascular market where Medicare is the dominant payer. Under RAPID, that wait becomes two months. The commercial model changes entirely.
Organogenesis completed its ReNu BLA submission last week for symptomatic knee osteoarthritis — a massive, underpenetrated musculoskeletal indication. If approved under a Breakthrough Device pathway, RAPID could materially accelerate the coverage timeline for a product the company is building as its primary alternative revenue engine in a post-CAMP-reset environment.
The Asymmetry That RAPID Creates
This is where the story gets strategically important for commercial, BD, and investment audiences.
RAPID eligibility requires a device to be the subject of an Investigational Device Exemption study that enrolls Medicare beneficiaries and studies clinical health outcomes agreed upon by FDA and CMS. That evidence bar — prospective, Medicare-enrolled, outcomes-focused — is not a bar that every company in this market can clear. It is specifically a bar that rewards companies that built their clinical development programs around real-world patient populations and hard endpoints.
Armstrong's critique of the evidence base in the BTK Signal Interview is directly applicable here. He described two failures: CTPs deployed too late as nth-line salvage in some clinics, and indiscriminately as first-line in others — both the predictable consequence of an ambiguous evidence base meeting a permissive payment structure. The companies that profited from that permissive structure cannot build the evidence package RAPID requires. It was never designed around clinical rigor.
RAPID, by contrast, is explicitly designed around it. The pathway rewards companies that invested in IDE-level clinical programs, enrolled Medicare beneficiaries, and studied outcomes that matter to patients — not surrogate endpoints that matter to sales teams.
The asymmetry is structural. Companies that built their commercial models around the old coverage pathway — where FDA clearance was sufficient to begin billing and coverage followed with time — are not the same companies positioned to benefit from RAPID. The companies that invested in the evidence infrastructure RAPID requires are mostly the same companies that survived the January 1 reimbursement reset intact.
The Broader Pattern
January 1 removed coverage for products that lacked clinical differentiation. RAPID accelerates coverage for products that demonstrate it. The same CMS administration that restructured skin substitute reimbursement in the most disruptive way in the sector's recent history is now building the fastest possible on-ramp for technologies that can prove they change patient outcomes.
This is not a contradiction. It is a coherent policy direction: clinical evidence is the currency. Companies that hold it get faster access. Companies that don't get a floor that reflects the actual value of their product.
Armstrong predicted that the field's shift toward pragmatic, registry-grade, real-world evidence is the most important change he is seeing in clinical adoption. RAPID institutionalizes that preference at the reimbursement level. The two developments — one clinical, one regulatory — are pointing in exactly the same direction.
The companies that understand this are already building for it. The companies that don't are still waiting for the coverage environment to return to what it was.
It won't.
This is The Take — BTK's Tuesday thesis edition. For the full weekly Market Signal including this week's Q1 earnings analysis, the DOJ seizure backstory, the Organogenesis ReNu BLA, and the complete events calendar, read the full edition at newsletter.belowtheknee.co.
The BTK Signal Interview with Dr. David Armstrong — Professor of Surgery, Keck School of Medicine, USC; Founder, SALSA; Co-founder, DFCon — is live at intelligence.belowtheknee.co/signal.
Not subscribed? → belowtheknee.co/newsletter
See you Friday. — Scott